Zika virus protection by a single low dose nucleoside modified mRNA vaccination

  title={Zika virus protection by a single low dose nucleoside modified mRNA vaccination},
  author={Norbert Pardi and Michael J Hogan and Rebecca S. Pelc and Hiromi Muramatsu and Hanne Andersen and Christina R DeMaso and Kimberly A. Dowd and Laura L. Sutherland and Richard M Scearce and Robert Parks and Wendeline Wagner and Alex Granados and Jack Greenhouse and Michelle Walker and Elinor Willis and Jae-Sung Yu and Charles E. McGee and Gregory D. Sempowski and Barbara L. Mui and Ying K. Tam and Yan-Jang S. Huang and Dana L Vanlandingham and Veronica M. Holmes and Harikrishnan Balachandran and Sujata Sahu and Michelle A. Lifton and Stephen Higgs and Scott E. Hensley and Thomas D. Madden and Michael J. Hope and Katalin Karik{\'o} and Sampa Santra and Barney S. Graham and Mark G. Lewis and Theodore C. Pierson and Barton F. Haynes and Drew Weissman},
  pages={248 - 251}
Zika virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology in newborns and adults. There are no ZIKV-specific treatments or preventatives. Therefore, the development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic proteins. Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsulated nucleoside… 
mRNA Vaccine Protects against Zika Virus
The data support the development of prM–E RNActive® as a promising mRNA vaccine against Zika to counter future epidemics.
Development of a potent Zika virus vaccine using self-amplifying messenger RNA
The development of ZIKV vaccine candidates are described using the self-amplifying messenger RNA (SAM) platform technology delivered by cationic nanoemulsion (CNE) that allows bedside mixing and is particularly useful for rapid responses to pandemic outbreaks.
A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus
A VSV-based Zika virus vaccine protects mice from lethal challenge
VSV-ZIKV vectors are promising vaccine candidates and should move forward along the licensure pathway and can uniformly protect mice from lethal disease when administered as late as 3 days prior to ZIKV challenge.
Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus
These studies confirm that ZikV VLPs could be efficiently generated and purified and support translational efforts in developing a ZIKV VLP vaccine for evaluation in human clinical trials.
A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates
The immunogenicity and protective efficacy of the recombinant subunit vaccine candidate in NHPs are demonstrated as well as the importance of neutralizing antibodies in protection against ZIKV infection and their potential implication as a correlate of protection are highlighted.
A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein
It is demonstrated that attenuated rVSV co-expressing prM, E, and NS1 is a promising vaccine candidate for protection against ZIKV infection and highlights an important role for NS1 in ZikV-specific cellular immune responses.
Immunization with truncated envelope protein of Zika virus induces protective immune response in mice
It is indicated that recombinant ZIKV E90, cloned and expressed in Escherichia coli, represents as a promising ZikV subunit vaccine that deserves further clinical development.


Vaccine Protection Against Zika Virus from Brazil
It is demonstrated that protection against ZIKV challenge can be achieved by single-shot subunit and inactivated virus vaccines in mice and that Env-specific antibody titers represent key immunologic correlates of protection.
Rapid development of a DNA vaccine for Zika virus
It is found that vaccination with DNA expressing the premembrane and envelope proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZikV challenge correlated with serum neutralizing activity.
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
In mice lacking receptors for interferon (IFN)-α/β (designated IFNAR−/−) immunisation with this DNA vaccine induced, following in vivo viral challenge, 100% protection against infection-associated weight loss or death in addition to preventing viral pathology in brain tissue.
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys
It is demonstrated that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys, and these data support the rapid clinical development of ZikV vaccines for humans.
A rhesus macaque model of Asian-lineage Zika virus infection
It is shown that rhesus macaques are susceptible to infection by an Asian-lineage ZIKV closely related to strains currently circulating in the Americas, and provides a relevant animal model for studying pathogenesis and evaluating potential interventions against human infection, including during pregnancy.
A Mouse Model of Zika Virus Pathogenesis.
Variation of the Specificity of the Human Antibody Responses after Tick-Borne Encephalitis Virus Infection and Vaccination
New in vitro assays for dissecting the antibody populations present in blood serum and determining their contribution to virus neutralization are developed, indicating substantial influences of individual-specific factors that control the specificity of the antibody response.